

Pharmaceutical Policies Updates Effective August 1, 2022

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective August 1, 2022 and will be available for viewing on or before July 1, 2022. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Zoladex Medicaid – Effective 05/14/2022	New
Enteral Therapy- New York	Updated
Enteral Therapy- Vermont	Updated
Rinvoq – Effective 06/01/2022	New
Aduhelm	Updated
Medicare Part B vs Part D Determination	Reviewed/No Changes
Copay Adjustment for Medical Necessity	Reviewed/No Changes
Infliximab – Effective 01/01/2022	Updated

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

